Pfizer Inc. and Array BioPharma Inc. entered into a clinical trial collaboration agreement to study the combination of several cancer immunotherapies.
The collaboration includes the study of Array's binimetinib with Pfizer's investigational talazoparib and avelumab. The companies will conduct a phase 1b trial along with a dose-establishing trial.
Initially the focus will be in non-small cell lung cancer and pancreatic cancer, and additional indications will be explored at a later stage. The study is expected to begin by the third quarter of 2018.
Pfizer will sponsor and fund the trial and Array will provide binimetinib supply.
Avelumab, or Bavencio, is jointly developed by Merck KGaA and Pfizer. It was granted accelerated approval by the U.S. Food and Drug Administration for Merkel cell carcinoma and metastatic urothelial carcinoma.
